['diabetes', 'diabetes mellitus, type 2']
['insulin degludec', 'insulin glargine']

        Inclusion Criteria: - Male or female, age at least 18 years at the time of signing informed
        consent - Subjects fulfilling at least one of the below criteria: a) Experienced at least
        one severe hypoglycaemic episode within last year (according to the ADA (American Diabetes
        Association) definition, April 2013), b) Moderate chronic renal failure, defined as
        glomerular filtration rate 30 - 59 mL/min/1.73 m^2 per CKD-Epi (Chronic Kidney Disease
        Epidemiology Collaboration) by central laboratory analysis, c) Hypoglycaemic symptom
        unawareness, d) Exposed to insulin for more than 5 years, e) Recent episode of
        hypoglycaemia (defined by symptoms of hypoglycaemia and/or episode with low glucose
        measurement (below or equal to 70 mg/dL [below or equal to 3.9 mmol/L])) within the last 12
        weeks prior to Visit 1 (screening) - Type 2 diabetes mellitus (diagnosed clinically) for at
        least 26 weeks prior to Visit 1 - Current treatment with any basal insulin (OD or BID) ±
        any combination of OADs (metformin, DPP-4 inhibitor, alpha-glucosidase inhibitor,
        thiazolidinediones, and SGLT2-inhibitor) for 26 weeks or longer prior to Visit 1 For
        subjects on BID the total daily dose should be below 75 units - HbA1c (glycosylated
        haemoglobin) below or equal to 9.5 % by central laboratory analysis - BMI (body mass index)
        below or equal to 45 kg/m^2 Exclusion Criteria: - Treatment with a bolus insulin separately
        or contained in an insulin mix product within the last 26 weeks prior to Visit 1 - Use of
        any other anti-diabetic agent(s) than those stated in the inclusion criteria within the
        last 26 weeks prior to Visit 1
      